Search Results

The multi-billion deal, in which Eli Lilly will acquire Scorpion Therapeutics’ STX-478 program, is a shot in the arm for PI3K treatments, which have had a mixed history over the past few years.

Scorpion Biological Services announced it has changed its name to Scorpius BioManufacturing reflecting the company’s recently expanded manufacturing capabilities and the grand opening of its new biomanufacturing facility in San Antonio in October.

In October 2023, Sino Biological, Inc. opened its Center for Bioprocessing (C4B) in Houston, Texas. The C4B represents a considerable global expansion of the company’s contract research service capabilities.

Scorpion Biological Services, a fully integrated contract research and contract development & manufacturing organization focused on the development of biologic drugs, hosted the grand opening of its new, state-of-the-art San Antonio facility on Friday, October 21, 2022.

Scorpion Therapeutics, Inc. today announced the appointment of Jeff Albers as a strategic advisor to the company.

Scorpion Therapeutics, Inc. announced leadership changes intended to position the Company for its next phase of growth, including the appointment of Adam Friedman, M.D., Ph.D., as Chief Executive Officer.

NightHawk Biosciences announced the appointment of Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services.

Biopharmaceutical contract development and manufacturing organization Scorpion Biological Services announced a planned development partnership with a private developer, the State of Kansas, and local and university affiliates, which will support the construction of a new biodefense-focused large molecule and biologics biomanufacturing facility in Manhattan, Kansas.